A detailed history of Ameriprise Financial Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Ameriprise Financial Inc holds 17,936 shares of SAVA stock, worth $468,847. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,936
Previous 20,001 10.32%
Holding current value
$468,847
Previous $247,000 113.36%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$9.57 - $35.08 $19,762 - $72,440
-2,065 Reduced 10.32%
17,936 $527,000
Q2 2024

Aug 14, 2024

BUY
$12.35 - $26.11 $43,756 - $92,507
3,543 Added 21.53%
20,001 $247,000
Q1 2024

May 15, 2024

SELL
$18.44 - $26.41 $11,893 - $17,034
-645 Reduced 3.77%
16,458 $333,000
Q4 2023

Feb 14, 2024

SELL
$12.64 - $30.11 $31,600 - $75,275
-2,500 Reduced 12.75%
17,103 $384,000
Q3 2023

Nov 14, 2023

SELL
$16.64 - $25.32 $124,783 - $189,874
-7,499 Reduced 27.67%
19,603 $326,000
Q2 2023

Aug 14, 2023

SELL
$21.59 - $27.88 $122,458 - $158,135
-5,672 Reduced 17.31%
27,102 $664,000
Q1 2023

May 15, 2023

BUY
$23.46 - $36.44 $593,373 - $921,676
25,293 Added 338.1%
32,774 $790,000
Q4 2022

Feb 14, 2023

BUY
$27.82 - $44.16 $10,293 - $16,339
370 Added 5.2%
7,481 $220,000
Q3 2022

Nov 14, 2022

BUY
$16.33 - $51.06 $116,122 - $363,087
7,111 New
7,111 $298,000
Q1 2022

May 16, 2022

SELL
$32.6 - $53.05 $197,556 - $321,483
-6,060 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$36.77 - $90.91 $202,602 - $500,914
-5,510 Reduced 47.62%
6,060 $265,000
Q3 2021

Nov 15, 2021

BUY
$41.79 - $135.3 $230,639 - $746,720
5,519 Added 91.21%
11,570 $718,000
Q2 2021

Aug 16, 2021

SELL
$32.15 - $89.72 $277,840 - $775,360
-8,642 Reduced 58.82%
6,051 $517,000
Q1 2021

May 17, 2021

BUY
$7.09 - $87.95 $17,441 - $216,357
2,460 Added 20.11%
14,693 $661,000
Q4 2020

Feb 12, 2021

BUY
$6.79 - $12.25 $83,062 - $149,854
12,233 New
12,233 $83,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.05B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.